Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Venclexta (Venetoclax) is a targeted cancer therapy manufactured by AbbVie and Genentech (Roche). It is FDA-approved to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) in adults. Unlike traditional chemotherapy, Venclexta is a precision medicine that targets a specific protein called BCL-2 that cancer cells use to survive.
For CLL and SLL, Venclexta can be used alone or in combination with other medications like Obinutuzumab, Rituximab, or Acalabrutinib. For newly diagnosed AML in patients aged 75 or older (or those who cannot tolerate intensive chemotherapy), it is used in combination with Azacitidine, Decitabine, or low-dose Cytarabine.
Venclexta is a selective BCL-2 inhibitor. BCL-2 is an anti-apoptotic protein — essentially a survival signal that cancer cells overexpress to avoid programmed cell death (apoptosis). By binding directly to the BCL-2 protein, Venclexta displaces pro-apoptotic proteins, restoring the cancer cell's natural self-destruct mechanism. This causes the cancer cells to undergo apoptosis and die.
This targeted approach is particularly effective in blood cancers like CLL, SLL, and AML, where BCL-2 overexpression is a key driver of tumor survival. Because Venclexta works so effectively at killing cancer cells, patients must follow a gradual dose ramp-up schedule to reduce the risk of tumor lysis syndrome (TLS) — a potentially dangerous condition caused by the rapid breakdown of large numbers of cancer cells.
For CLL/SLL, patients follow a 5-week dose ramp-up: 20 mg daily (week 1) → 50 mg (week 2) → 100 mg (week 3) → 200 mg (week 4) → 400 mg daily (week 5 onward). For AML, the ramp-up is faster: 100 mg (day 1) → 200 mg (day 2) → 400 mg (day 3 onward).
Venclexta scores a 40 out of 100 on our findability scale, meaning it can be quite difficult to access. While there is no active FDA shortage, Venclexta is a specialty oncology medication distributed exclusively through specialty pharmacies. This distribution model, combined with mandatory prior authorization from insurance companies, creates significant access delays. Patients frequently report waiting days to weeks for prescriptions to be processed and shipped. If your oncologist prescribes Venclexta, expect to work closely with a specialty pharmacy coordinator to navigate insurance approvals and delivery logistics.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Venclexta is prescribed exclusively by cancer specialists:
Due to the risk of tumor lysis syndrome and the need for close blood work monitoring during the ramp-up phase, Venclexta is not prescribed by primary care physicians. Your oncology team will coordinate with a specialty pharmacy to manage your prescription. Venclexta is not available via telehealth — it requires in-person oncology care with regular lab monitoring.
No, Venclexta is not a controlled substance. It is not classified under any DEA schedule. However, it is a specialty medication with restricted distribution — you cannot fill it at a regular retail pharmacy. Venclexta is dispensed through specialty pharmacies that have the infrastructure to handle high-cost oncology medications, manage cold chain requirements, and coordinate insurance prior authorizations.
Serious side effects include tumor lysis syndrome (TLS), which can cause kidney failure and is potentially fatal. Severe neutropenia increases risk of serious infections including pneumonia and sepsis. Your oncology team will monitor your blood counts closely, especially during the first weeks of treatment. Contact your doctor immediately if you develop fever, chills, signs of infection, or unusual bleeding or bruising.
If Venclexta is not an option, your oncologist may consider these alternatives for CLL/SLL:
These alternatives work through different mechanisms and may be appropriate depending on your specific diagnosis, prior treatments, and overall health. Always discuss options with your oncologist.
Venclexta has several important drug interactions that your oncologist will manage carefully:
Food interactions: Avoid grapefruit, Seville oranges, and starfruit during treatment as they inhibit CYP3A and can increase Venclexta levels. Always take Venclexta with food to improve absorption and reduce TLS risk.
Venclexta represents a breakthrough in targeted cancer therapy for patients with CLL, SLL, and AML. As a BCL-2 inhibitor, it offers a precision approach to fighting blood cancers without traditional chemotherapy. However, accessing Venclexta can be challenging — the specialty pharmacy distribution model, prior authorization requirements, and high cost ($15,000–$16,000/month without assistance) create real barriers for patients.
The good news: manufacturer co-pay assistance programs from Genentech and AbbVie can bring out-of-pocket costs to $0 for eligible commercially insured patients. Uninsured patients may qualify for free medication through the Genentech Patient Foundation. If you've been prescribed Venclexta, work closely with your oncology team's financial counselor and the Genentech Access Solutions program to maximize your coverage.
If you're having trouble finding Venclexta or navigating the specialty pharmacy process, Medfinder can help connect you with resources and availability information.
%2C%20Color%3DOriginal.png)
